{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:26:17Z","timestamp":1790623577858,"version":"4.1.0"},"reference-count":178,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institute of Health","award":["DK061652"],"award-info":[{"award-number":["DK061652"]}]},{"name":"National Institute of Health","award":["GM107058"],"award-info":[{"award-number":["GM107058"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.apsb.2016.07.016","type":"journal-article","created":{"date-parts":[[2016,9,11]],"date-time":"2016-09-11T22:47:05Z","timestamp":1473634025000},"page":"413-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Insights into CYP2B6-mediated drug\u2013drug interactions"],"prefix":"10.1016","volume":"6","author":[{"given":"William D.","family":"Hedrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem E.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2016.07.016_bib1","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/dmd.31.12.1461","article-title":"A passion for P450s (remembrances of the early history of research on cytochrome P450)","volume":"31","author":"Estabrook","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008571-199602000-00002","article-title":"P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature","volume":"6","author":"Nelson","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.apsb.2016.07.016_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008571-200401000-00001","article-title":"Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants","volume":"14","author":"Nelson","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.apsb.2016.07.016_bib4","first-page":"1480","article-title":"CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson\u05f3s disease, as revealed from experiments with recombinant enzymes","volume":"29","author":"Hidestrand","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2007.10.024","article-title":"Cytochrome P450s in the development of target-based anticancer drugs","volume":"259","author":"Purnapatre","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2016.07.016_bib6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00008571-200111000-00007","article-title":"Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19","volume":"11","author":"Hoffman","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.apsb.2016.07.016_bib7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0090-9556(25)08198-X","article-title":"Characterization of cytochrome P-450 2B6 in human liver microsomes.","volume":"21","author":"Mimura","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0090-9556(24)15215-4","article-title":"Monospecific antipeptide antibody to cytochrome P-450 2B6","volume":"27","author":"Stresser","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib10","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0026-895X(24)12054-8","article-title":"Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity","volume":"28","author":"Faucette","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib11","first-page":"985","article-title":"Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation","volume":"25","author":"Code","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/abbi.2000.1708","article-title":"Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver","volume":"376","author":"Hanna","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.apsb.2016.07.016_bib13","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","article-title":"CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants","volume":"28","author":"Hesse","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"Wang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.apsb.2016.07.016_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1081\/DMR-120001392","article-title":"Summary of information on human CYP enzymes: human P450 metabolism data","volume":"34","author":"Rendic","year":"2002","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.apsb.2016.07.016_bib16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.pharmthera.2006.10.002","article-title":"The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals","volume":"113","author":"Hodgson","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/138920006776873508","article-title":"Induction of the hepatic cytochrome P450 2B subfamily by xenobiotics: research history, evolutionary aspect, relation to tumorigenesis, and mechanism","volume":"7","author":"Yamada","year":"2006","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.apsb.2016.07.016_bib18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2125.1999.00044.x","article-title":"Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin","volume":"48","author":"Svensson","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00000542-200101000-00021","article-title":"Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes","volume":"94","author":"Court","year":"2001","journal-title":"Anesthesiology"},{"key":"10.1016\/j.apsb.2016.07.016_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and mitotic effects of methadone","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0090-9556(24)02975-1","article-title":"CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes","volume":"32","author":"Ram\u00edrez","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.tpj.6500157","article-title":"Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation","volume":"3","author":"Xie","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.apsb.2016.07.016_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib24","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/QAD.0b013e3282ef9695","article-title":"CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children","volume":"21","author":"Saitoh","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.apsb.2016.07.016_bib25","first-page":"887","article-title":"Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes","volume":"29","author":"Yanagihara","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejps.2004.10.006","article-title":"Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay","volume":"24","author":"Turpeinen","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2016.07.016_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clpt.2006.03.010","article-title":"Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity","volume":"80","author":"Loboz","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/dmd.32.6.626","article-title":"Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro","volume":"32","author":"Turpeinen","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/dmd.30.7.853","article-title":"Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes","volume":"30","author":"Hijazi","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib30","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0006-2952(96)00052-4","article-title":"Multiple forms of human P450 expressed in Saccharomyces cerevisiae: systematic characterization and comparison with those of the rat","volume":"51","author":"Imaoka","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1365-2125.2001.00344.x","article-title":"Involvement of human liver cytochrome P4502B6 in the metabolism of propofol","volume":"51","author":"Oda","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/0049825021000017948","article-title":"Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine","volume":"33","author":"Labb\u00e8","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1016\/j.apsb.2016.07.016_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00008571-199706000-00001","article-title":"Examination of purported probes of human CYP2B6","volume":"7","author":"Ekins","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.apsb.2016.07.016_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0278-6915(99)00010-1","article-title":"Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment","volume":"37","author":"Lake","year":"1999","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.apsb.2016.07.016_bib35","first-page":"775","article-title":"Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6","volume":"26","author":"Ko","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib36","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0090-9556(24)14953-7","article-title":"Role of human CYP2B6 in S-mephobarbital N-demethylation","volume":"27","author":"Kobayashi","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","article-title":"Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype","volume":"94","author":"Kiang","year":"2006","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.apsb.2016.07.016_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/004982599238731","article-title":"Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine","volume":"29","author":"Niwa","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1016\/j.apsb.2016.07.016_bib39","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1248\/bpb.23.498","article-title":"Inhibition of drug-metabolizing enzyme activity in human hepatic cytochrome P450s by bisphenol A","volume":"23","author":"Niwa","year":"2000","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.apsb.2016.07.016_bib40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0009-9236(96)90001-6","article-title":"Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation","volume":"59","author":"Engel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib41","first-page":"1383","article-title":"In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone","volume":"25","author":"Surapaneni","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib42","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1124\/dmd.111.040352","article-title":"Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether","volume":"39","author":"Honda","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib43","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1124\/mol.104.009019","article-title":"Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor","volume":"67","author":"Burk","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib44","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens","volume":"319","author":"Tsuchiya","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2016.07.016_bib45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.apsb.2016.07.016_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.apsb.2016.07.016_bib47","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib48","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1124\/dmd.30.7.814","article-title":"The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes","volume":"30","author":"Lindley","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib49","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0006-2952(99)00410-4","article-title":"Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide","volume":"59","author":"Huang","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib50","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15302-0","article-title":"Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles","volume":"27","author":"Roy","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib51","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0090-9556(24)14934-3","article-title":"Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer","volume":"27","author":"Roy","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2125.2002.01614.x","article-title":"The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver","volume":"54","author":"Coller","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/carcin\/15.1.5","article-title":"Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s","volume":"15","author":"Styles","year":"1994","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.apsb.2016.07.016_bib54","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1124\/dmd.31.9.1093","article-title":"Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems","volume":"31","author":"Salonen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"10.1016\/j.apsb.2016.07.016_bib56","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1248\/bpb.28.1711","article-title":"Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs","volume":"28","author":"Niwa","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.apsb.2016.07.016_bib57","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3109\/00498259609050260","article-title":"Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily","volume":"26","author":"Onof","year":"1996","journal-title":"Xenobiotica"},{"key":"10.1016\/j.apsb.2016.07.016_bib58","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0006-2952(98)00018-5","article-title":"Inhibitory monoclonal antibody to human cytochrome P450 2B6","volume":"55","author":"Yang","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib59","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0022-3565(24)37719-5","article-title":"Further characterization of the expression in liver and catalytic activity of CYP2B6","volume":"286","author":"Ekins","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib60","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.apsb.2016.07.016_bib61","first-page":"36","article-title":"Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes","volume":"29","author":"Kobayashi","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib62","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1124\/dmd.30.12.1329","article-title":"Enantioselective metabolism of the endocrine disruptor pesticide methoxychlor by human cytochromes P450 (P450s): major differences in selective enantiomer formation by various P450 isoforms","volume":"30","author":"Hu","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib63","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/dmd.30.9.1035","article-title":"Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite","volume":"30","author":"Hu","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib64","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0090-9556(25)08439-9","article-title":"Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B","volume":"22","author":"Dehal","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib65","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression","volume":"307","author":"Lamba","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib66","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.apsb.2016.07.016_bib67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00008571-200404000-00002","article-title":"Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes","volume":"14","author":"Hesse","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.apsb.2016.07.016_bib68","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0022-5347(24)07181-7","article-title":"Induction of the unspecific microsomal hydroxylase in the human liver","volume":"1","author":"Remmer","year":"1973","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib69","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0026-895X(24)12603-X","article-title":"Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor","volume":"60","author":"Goodwin","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib70","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1124\/jpet.105.098160","article-title":"Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor","volume":"317","author":"Faucette","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib71","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/07853890310008224","article-title":"Drug-activated nuclear receptors CAR and PXR","volume":"35","author":"Honkakoski","year":"2003","journal-title":"Ann Med"},{"key":"10.1016\/j.apsb.2016.07.016_bib72","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/17425255.2013.754010","article-title":"Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond","volume":"9","author":"Chai","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.apsb.2016.07.016_bib73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd753","article-title":"PXR, CAR and drug metabolism","volume":"1","author":"Willson","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2016.07.016_bib74","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.biomaterials.2012.10.073","article-title":"PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers","volume":"34","author":"Lu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2016.07.016_bib75","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1081\/DMR-100101942","article-title":"The role of CYP2B6 in human xenobiotic metabolism","volume":"31","author":"Ekins","year":"1999","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.apsb.2016.07.016_bib76","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.apsb.2016.07.016_bib77","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s11095-006-9083-5","article-title":"Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese","volume":"23","author":"Guan","year":"2006","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2016.07.016_bib78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2007.02884.x","article-title":"CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV\/AIDS treatment","volume":"64","author":"Mehlotra","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/jpet.104.068973","article-title":"Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles","volume":"311","author":"Lang","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib80","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":"Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver","volume":"325","author":"Hofmann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib81","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.109.031393","article-title":"Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation","volume":"38","author":"Ogburn","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib82","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1124\/dmd.111.042416","article-title":"Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo","volume":"40","author":"Xu","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib83","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.apsb.2016.07.016_bib84","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/QAD.0b013e32830163ad","article-title":"Clinical impact of patient population differences and genomic variation in efavirenz therapy","volume":"22","author":"King","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.apsb.2016.07.016_bib85","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FPC.0b013e328336eee4","article-title":"ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir","volume":"20","author":"Lubomirov","year":"2010","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.apsb.2016.07.016_bib86","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-011-1118-0","article-title":"CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans","volume":"68","author":"Maimbo","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib87","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2016.07.016_bib88","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/tpj.2011.34","article-title":"High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of na\u00efve HIV patients from Ethiopia: a prospective cohort study","volume":"12","author":"Yimer","year":"2012","journal-title":"Pharmacogenom J"},{"key":"10.1016\/j.apsb.2016.07.016_bib89","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/499364","article-title":"Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study","volume":"42","author":"Ribaudo","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2016.07.016_bib90","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/infdis\/jiq043","article-title":"Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study","volume":"203","author":"Lubomirov","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2016.07.016_bib91","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkr272","article-title":"Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens","volume":"66","author":"Wyen","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2016.07.016_bib92","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0b013e3181f0634c","article-title":"The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy","volume":"32","author":"Cabrera Figueroa","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.apsb.2016.07.016_bib93","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1086\/499369","article-title":"Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance","volume":"42","author":"Nolan","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2016.07.016_bib94","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2217\/pgs.14.48","article-title":"Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics","volume":"15","author":"Mart\u00edn","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.apsb.2016.07.016_bib95","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jac\/dkl524","article-title":"Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors","volume":"59","author":"Rivero","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2016.07.016_bib96","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/pgs.09.142","article-title":"Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique","volume":"11","author":"Ciccacci","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.apsb.2016.07.016_bib97","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/jac\/dkr087","article-title":"Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals","volume":"66","author":"Schipani","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2016.07.016_bib98","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FTD.0b013e31824868f3","article-title":"Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals","volume":"34","author":"Heil","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.apsb.2016.07.016_bib99","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/pgs.11.132","article-title":"Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians","volume":"13","author":"Brown","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.apsb.2016.07.016_bib100","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":"Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients","volume":"61","author":"Wyen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2016.07.016_bib101","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.111.039586","article-title":"Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262","volume":"39","author":"Ariyoshi","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib102","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2013-07-516666","article-title":"CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia","volume":"122","author":"Johnson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2016.07.016_bib103","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1002\/cncr.22669","article-title":"Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma","volume":"109","author":"Chugh","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.apsb.2016.07.016_bib104","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/03602530500364023","article-title":"Metabolism and transport of oxazaphosphorines and the clinical implications","volume":"37","author":"Zhang","year":"2005","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.apsb.2016.07.016_bib105","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00467-004-1807-3","article-title":"Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity","volume":"20","author":"Aleksa","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.apsb.2016.07.016_bib106","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bbmt.2015.02.001","article-title":"Cytochrome P450 2B6*5 increases relapse after cyclophosphamide-containing conditioning and autologous transplantation for lymphoma","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol Blood Marrow Transpl."},{"key":"10.1016\/j.apsb.2016.07.016_bib107","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1365-2125.2010.03789.x","article-title":"The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation","volume":"70","author":"Helsby","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib108","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/01213011-200512000-00004","article-title":"Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz","volume":"15","author":"Klein","year":"2005","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.apsb.2016.07.016_bib109","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2217\/pgs.11.160","article-title":"Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV\/AIDS treatment","volume":"13","author":"Li","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.apsb.2016.07.016_bib110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz","volume":"16","author":"Wang","year":"2006","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.apsb.2016.07.016_bib111","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1124\/mol.104.008086","article-title":"A natural CYP2B6 TATA box polymorphism (\u221282T>C) leading to enhanced transcription and relocation of the transcriptional start site","volume":"67","author":"Zukunft","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib112","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00228-006-0163-6","article-title":"Absence of CYP2B6 promoter \u221282T>C mutation in Chinese as an additional factor for slow metabolism of drugs commonly used in infections","volume":"62","author":"He","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib113","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/mol.110.065185","article-title":"Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation","volume":"78","author":"Li","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib114","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/jpet.111.183111","article-title":"Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex","volume":"338","author":"Zhang","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/FPC.0b013e328045c4fb","article-title":"Genetic polymorphisms of CYP2B6 affect the pharmacokinetics\/pharmacodynamics of cyclophosphamide in Japanese cancer patients","volume":"17","author":"Nakajima","year":"2007","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.apsb.2016.07.016_bib116","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1016\/S0021-9258(20)82030-4","article-title":"Transcriptional regulation of rat liver epoxide hydratase, NADPH-cytochrome P-450 oxidoreductase, and cytochrome P-450b genes by phenobarbital.","volume":"258","author":"Hardwick","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2016.07.016_bib117","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.pharmtox.41.1.123","article-title":"Phenobarbital response elements of cytochrome P450 genes and nuclear receptors","volume":"41","author":"Sueyoshi","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.apsb.2016.07.016_bib118","doi-asserted-by":"crossref","first-page":"9746","DOI":"10.1074\/jbc.271.16.9746","article-title":"Characterization of phenobarbital-inducible mouse Cyp2b10 gene transcription in primary hepatocytes","volume":"271","author":"Honkakoski","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2016.07.016_bib119","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0300-483X(98)00085-7","article-title":"Comparison of the effects of some CYP3A and other enzyme inducers on replicative DNA synthesis and cytochrome P450 isoforms in rat liver","volume":"131","author":"Lake","year":"1998","journal-title":"Toxicology"},{"key":"10.1016\/j.apsb.2016.07.016_bib120","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI116064","article-title":"Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes","volume":"90","author":"Kolars","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2016.07.016_bib121","doi-asserted-by":"crossref","first-page":"17277","DOI":"10.1074\/jbc.M300138200","article-title":"Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes","volume":"278","author":"Maglich","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2016.07.016_bib122","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0928-0987(01)00135-X","article-title":"Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation","volume":"13","author":"LeCluyse","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2016.07.016_bib123","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1124\/mol.58.6.1441","article-title":"Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation","volume":"58","author":"Pascussi","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib124","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0378-1119(94)00916-G","article-title":"Localization of a phenobarbital-responsive element (PBRE) in the 5\u02b9-flanking region of the rat Cyp2b2 gene","volume":"158","author":"Trottier","year":"1995","journal-title":"Gene"},{"key":"10.1016\/j.apsb.2016.07.016_bib125","doi-asserted-by":"crossref","first-page":"23725","DOI":"10.1074\/jbc.271.39.23725","article-title":"Phenobarbital induction mediated by a distal CYP2B2 sequence in rat liver transiently transfected in situ","volume":"271","author":"Park","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2016.07.016_bib126","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1128\/MCB.18.10.5652","article-title":"The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene","volume":"18","author":"Honkakoski","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2016.07.016_bib127","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1074\/jbc.M800729200","article-title":"Nuclear receptor CAR requires early growth response 1 to activate the human cytochrome P450 2B6 gene","volume":"283","author":"Inoue","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2016.07.016_bib128","doi-asserted-by":"crossref","first-page":"14146","DOI":"10.1074\/jbc.M212482200","article-title":"A novel distal enhancer module regulated by pregnane X receptor\/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression","volume":"278","author":"Wang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2016.07.016_bib129","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/mol.53.4.597","article-title":"Activation by diverse xenochemicals of the 51-base pair phenobarbital-responsive enhancer module in the CYP2B10 gene","volume":"53","author":"Honkakoski","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib130","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1074\/jbc.274.10.6043","article-title":"The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene","volume":"274","author":"Sueyoshi","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2016.07.016_bib131","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/35038112","article-title":"The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism","volume":"407","author":"Wei","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2016.07.016_bib132","doi-asserted-by":"crossref","first-page":"12822","DOI":"10.1074\/jbc.M005930200","article-title":"Orphan receptor promiscuity in the induction of cytochromes p450 by xenobiotics","volume":"276","author":"Smirlis","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2016.07.016_bib133","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1128\/MCB.24.18.7931-7940.2004","article-title":"Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes","volume":"24","author":"Kodama","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2016.07.016_bib134","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1099-0461(1998)12:1<3::AID-JBT2>3.0.CO;2-P","article-title":"Regulatory DNA elements of phenobarbital-responsive cytochrome P450 CYP2B genes","volume":"12","author":"Honkakoski","year":"1998","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.apsb.2016.07.016_bib135","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1124\/mol.62.3.638","article-title":"Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification","volume":"62","author":"Maglich","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib136","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bcp.2015.08.087","article-title":"Genome-wide analysis of human constitutive androstane receptor (CAR) transcriptome in wild-type and CAR-knockout HepaRG cells","volume":"98","author":"Li","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib137","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1074\/jbc.M511116200","article-title":"A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway","volume":"281","author":"Zhou","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2016.07.016_bib138","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1124\/mol.107.041012","article-title":"Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression","volume":"73","author":"Roth","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib139","doi-asserted-by":"crossref","first-page":"14581","DOI":"10.1074\/jbc.M010173200","article-title":"Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin","volume":"276","author":"Geick","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2016.07.016_bib140","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1124\/dmd.31.5.620","article-title":"Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes","volume":"31","author":"Wang","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib141","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1124\/mol.62.3.737","article-title":"Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site","volume":"62","author":"Ferguson","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib142","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1053\/jhep.2001.24172","article-title":"The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR","volume":"33","author":"Sugatani","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2016.07.016_bib143","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0009-2797(01)00163-6","article-title":"Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics","volume":"134","author":"LeCluyse","year":"2001","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.apsb.2016.07.016_bib144","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/35019116","article-title":"Humanized xenobiotic response in mice expressing nuclear receptor SXR","volume":"406","author":"Xie","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2016.07.016_bib145","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/toxsci\/kfs321","article-title":"Expression of human CAR splicing variants in BAC-transgenic mice","volume":"132","author":"Zhang","year":"2013","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.apsb.2016.07.016_bib146","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1128\/MCB.19.9.6318","article-title":"Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene","volume":"19","author":"Kawamoto","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2016.07.016_bib147","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00008571-199906000-00004","article-title":"Human CYP2B6: expression, inducibility and catalytic activities","volume":"9","author":"Gervot","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.apsb.2016.07.016_bib148","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/dmd.108.022772","article-title":"Dexamethasone induction of murine CYP2B genes requires the glucocorticoid receptor","volume":"37","author":"Audet-Walsh","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib149","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/dmd.32.3.348","article-title":"Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers","volume":"32","author":"Faucette","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2016.07.016_bib150","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/mend.14.11.0547","article-title":"Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene","volume":"14","author":"Kawamoto","year":"2000","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2016.07.016_bib151","doi-asserted-by":"crossref","first-page":"R252","DOI":"10.1186\/bcr784","article-title":"Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma","volume":"6","author":"Bi\u00e8che","year":"2004","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.apsb.2016.07.016_bib152","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbagrm.2010.01.005","article-title":"Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells","volume":"1799","author":"Lo","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2016.07.016_bib153","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bcp.2012.03.016","article-title":"Estradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy","volume":"84","author":"Koh","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib154","doi-asserted-by":"crossref","first-page":"e0150587","DOI":"10.1371\/journal.pone.0150587","article-title":"Transcriptional regulation of CYP2B6 expression by hepatocyte nuclear factor 3\u03b2 in human liver cells","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2016.07.016_bib155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0014-5793(98)00746-7","article-title":"Re-expression of C\/EBP\u03b1 induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells","volume":"431","author":"Jover","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2016.07.016_bib156","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/j.febslet.2009.05.031","article-title":"Early growth response 1 loops the CYP2B6 promoter for synergistic activation by the distal and proximal nuclear receptors CAR and HNF4\u03b1","volume":"583","author":"Inoue","year":"2009","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2016.07.016_bib157","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1158\/1535-7163.MCT-15-0667","article-title":"Activation of the constitutive androstane receptor increases the therapeutic index of CHOP in lymphoma treatment","volume":"15","author":"Hedrich","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib158","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00228-003-0590-6","article-title":"Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes","volume":"59","author":"Griskevicius","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib159","first-page":"2344","article-title":"Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation","volume":"49","author":"Clarke","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2016.07.016_bib160","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0022-3565(24)38043-7","article-title":"In vivo modulation of alternative pathways of P-450\u2013catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity","volume":"288","author":"Yu","year":"1999","journal-title":"J Pharm Exp Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib161","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2012-06-436691","article-title":"The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies","volume":"121","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2016.07.016_bib162","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/17425250903483207","article-title":"Efavirenz in the therapy of HIV infection","volume":"6","author":"Rakhmanina","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.apsb.2016.07.016_bib163","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/QAI.0b013e318183a425","article-title":"Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects","volume":"49","author":"Robertson","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.apsb.2016.07.016_bib164","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2133\/dmpk.DMPK-12-RG-124","article-title":"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19","volume":"28","author":"Xu","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.apsb.2016.07.016_bib165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000252658","article-title":"Pharmacokinetic and toxicological profile of artemisinin compounds: an update","volume":"84","author":"Medhi","year":"2009","journal-title":"Pharmacology"},{"key":"10.1016\/j.apsb.2016.07.016_bib166","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0009-9236(98)90149-7","article-title":"Artemisinin induces omeprazole metabolism in human beings","volume":"64","author":"Svensson","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib167","first-page":"256","article-title":"Seizures and bupropion: a review","volume":"50","author":"Davidson","year":"1989","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.apsb.2016.07.016_bib168","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/01.jcp.0000162805.46453.e3","article-title":"Inhibition of CYP2D6 activity by bupropion","volume":"25","author":"Kotlyar","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib169","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00007691-199610000-00010","article-title":"Bupropion plasma levels and CYP2D6 phenotype","volume":"18","author":"Pollock","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.apsb.2016.07.016_bib170","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00610051","article-title":"Pharmacodynamic and pharmacokinetic interactions between ketamine and diazepam","volume":"24","author":"Idvall","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib171","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00000542-197509000-00007","article-title":"Interaction between sedative premedicants and ketamine in man in isolated perfused rat livers","volume":"43","author":"Lo","year":"1975","journal-title":"Anesthesiology"},{"key":"10.1016\/j.apsb.2016.07.016_bib172","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.apsb.2016.07.016_bib173","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/ewjm.172.1.11","article-title":"Toxicology and pathology of deaths related to methadone: retrospective review","volume":"172","author":"Karch","year":"2000","journal-title":"West J Med"},{"key":"10.1016\/j.apsb.2016.07.016_bib174","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"Eap","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.apsb.2016.07.016_bib175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00542464","article-title":"Comparative disposition of pethidine and norpethidine in old and young patients","volume":"22","author":"Holmberg","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2016.07.016_bib176","first-page":"289","article-title":"Norpethidine accumulation and generalized seizure during pethidine patient-controlled analgesia","volume":"27","author":"McHugh","year":"1999","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.apsb.2016.07.016_bib177","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/bja\/71.5.738","article-title":"Norpethidine toxicity and patient controlled analgesia","volume":"71","author":"Stone","year":"1993","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.apsb.2016.07.016_bib178","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1124\/dmd.112.046979","article-title":"Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts","volume":"40","author":"Sridar","year":"2012","journal-title":"Drug Metab Dispos"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383516302532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383516302532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:38:46Z","timestamp":1761928726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383516302532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":178,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S2211383516302532"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2016.07.016","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights into CYP2B6-mediated drug\u2013drug interactions","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2016.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}